MX2021010831A - Composiciones de ligando del cumulo de diferenciación 40 (cd40l) y métodos para regulación ajustable. - Google Patents

Composiciones de ligando del cumulo de diferenciación 40 (cd40l) y métodos para regulación ajustable.

Info

Publication number
MX2021010831A
MX2021010831A MX2021010831A MX2021010831A MX2021010831A MX 2021010831 A MX2021010831 A MX 2021010831A MX 2021010831 A MX2021010831 A MX 2021010831A MX 2021010831 A MX2021010831 A MX 2021010831A MX 2021010831 A MX2021010831 A MX 2021010831A
Authority
MX
Mexico
Prior art keywords
compositions
methods
cd40l
tunable regulation
tunable
Prior art date
Application number
MX2021010831A
Other languages
English (en)
Inventor
Celeste Richardson
Jennifer Leah Gori
Kutlu Goksu Elpek
Michelle Lynn Ols
Brian Dolinski
Mara Christine Inniss
dan jun Li
Michael Joseph Briskin
Dexue Sun
Dhruv Kam Sethi
Vipin Suri
Elizabeth Jane Weisman
Michael Schebesta
Michelle Lois Fleury
Steven Mark Shamah
Tariq A Kassum
Emily Brideau
Original Assignee
Obsidian Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obsidian Therapeutics Inc filed Critical Obsidian Therapeutics Inc
Publication of MX2021010831A publication Critical patent/MX2021010831A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)

Abstract

La presente descripción proporciona sistemas de biocircuitos regulables, módulos efectores y composiciones para inmunoterapia contra el cáncer. También se proporcionan métodos para inducir respuestas inmunitarias contra el cáncer en un sujeto.
MX2021010831A 2019-03-08 2020-03-06 Composiciones de ligando del cumulo de diferenciación 40 (cd40l) y métodos para regulación ajustable. MX2021010831A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962815404P 2019-03-08 2019-03-08
US201962835554P 2019-04-18 2019-04-18
US201962860356P 2019-06-12 2019-06-12
PCT/US2020/021582 WO2020185628A1 (en) 2019-03-08 2020-03-06 Cd40l compositions and methods for tunable regulation

Publications (1)

Publication Number Publication Date
MX2021010831A true MX2021010831A (es) 2021-12-15

Family

ID=70057353

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010831A MX2021010831A (es) 2019-03-08 2020-03-06 Composiciones de ligando del cumulo de diferenciación 40 (cd40l) y métodos para regulación ajustable.

Country Status (12)

Country Link
US (1) US20220175781A1 (es)
EP (1) EP3935077A1 (es)
JP (1) JP2022524509A (es)
KR (1) KR20210148106A (es)
CN (1) CN114174327A (es)
AU (2) AU2020236937B2 (es)
BR (1) BR112021017770A2 (es)
CA (1) CA3132817A1 (es)
IL (1) IL286130A (es)
MX (1) MX2021010831A (es)
SG (1) SG11202109225WA (es)
WO (1) WO2020185628A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220044266A (ko) * 2019-06-12 2022-04-07 옵시디안 테라퓨틱스, 인크. 조정 가능한 조절을 위한 ca2 조성물 및 방법
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
CA3233380A1 (en) * 2021-10-18 2023-04-27 Dhruv SETHI Compositions and systems for regulation of function/abundance and delivery of polypeptide payloads

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US8173792B2 (en) 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
WO2009045308A2 (en) 2007-10-03 2009-04-09 Fred Hutchinson Cancer Research Center Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression
US8530636B2 (en) 2008-05-07 2013-09-10 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells in vivo using synthetic small molecules
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
CA2798988C (en) 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
US9512401B2 (en) 2010-10-01 2016-12-06 Board Of Regents, The University Of Texas System B and T lymphocyte attenuator marker for use in adoptive T-cell therapy
WO2012122025A2 (en) 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
CN104321425B (zh) 2012-05-07 2018-08-10 株式会社Nkmax 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
US20140255361A1 (en) * 2013-03-07 2014-09-11 The Board Of Trustees Of The Leland Stanford Junior University Estrogen-receptor based ligand system for regulating protein stability
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
WO2015152813A1 (en) 2014-04-03 2015-10-08 Deniz Kirik Gene expression system and regulation thereof
US9888673B2 (en) * 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3270976A4 (en) 2015-03-20 2019-02-27 The Trustees of the University of Pennsylvania VACCINES WITH CD40 LIGAND AS ADJUVANS
WO2016161516A1 (en) 2015-04-10 2016-10-13 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
JP7114457B2 (ja) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
AR105433A1 (es) 2015-07-21 2017-10-04 Novartis Ag Métodos para mejorar la eficacia y expansión de las células inmunes
WO2017156238A1 (en) 2016-03-11 2017-09-14 President And Fellows Of Harvard College Protein stability-based small molecule biosensors and methods
WO2017175072A1 (en) 2016-04-08 2017-10-12 Feldan Bio Inc. Peptide shuttle based gene disruption
AU2017250773A1 (en) * 2016-04-14 2018-11-08 2Seventy Bio, Inc. Salvage chimeric antigen receptor systems
MX2018012615A (es) 2016-04-15 2019-05-30 Novartis Ag Composiciones y metodos para la expresion selectiva de proteinas.
US20190300864A1 (en) 2016-05-20 2019-10-03 Braingene Ab Destabilising domains for conditionally stabilising a protein
US20220204582A1 (en) * 2016-12-02 2022-06-30 University Of Southern California Synthetic immune receptors and methods of use thereof
KR20200010181A (ko) * 2017-03-03 2020-01-30 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역치료를 위한 방법
WO2018160993A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
WO2018161038A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il12 compositions and methods for immunotherapy
WO2018161000A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Dhfr tunable protein regulation
WO2018213747A1 (en) * 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. 4-1bb agonist and cd40 agonist bispecific molecules
MX2019014960A (es) * 2017-06-12 2020-08-06 Obsidian Therapeutics Inc Composiciones de fosfodiesterasa de tipo 5 (pde5) y métodos de inmunoterapia.
US11891634B2 (en) 2017-06-23 2024-02-06 The Board Of Trustees Of The Leland Stanford Junior University PDE5A destabilizing domains
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy

Also Published As

Publication number Publication date
AU2023219954A1 (en) 2023-09-14
KR20210148106A (ko) 2021-12-07
CN114174327A (zh) 2022-03-11
SG11202109225WA (en) 2021-09-29
BR112021017770A2 (pt) 2021-11-16
EP3935077A1 (en) 2022-01-12
AU2020236937B2 (en) 2023-06-15
JP2022524509A (ja) 2022-05-06
AU2020236937A1 (en) 2021-09-23
CA3132817A1 (en) 2020-09-17
WO2020185628A1 (en) 2020-09-17
US20220175781A1 (en) 2022-06-09
IL286130A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
MX2021010831A (es) Composiciones de ligando del cumulo de diferenciación 40 (cd40l) y métodos para regulación ajustable.
BR112021017744A2 (pt) Composições e métodos de cd40l para regulação ajustável
SG11202108644UA (en) Modified natural killer (nk) cells for immunotherapy
EP3865025A3 (en) Cooking device and components thereof
WO2018109174A3 (en) Il-11 antibodies
SG11202010570VA (en) Immune effector cells and molecular adaptors with an antigen-cytokine complex for effective immunotherapy
MX2020003125A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
PH12020551291A1 (en) Alcoholic beverages produced from individual components
IL286183A (en) Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment
MX2021004477A (es) Componentes recombinantes y composiciones para usarse en productos alimenticios.
MX2021006181A (es) Una capsula de bebida.
WO2018218085A3 (en) THREE-DIMENSIONAL PRINTED ORGANS, DEVICES, AND ARRAYS
WO2016073794A8 (en) Methods of producing two chain proteins in bacteria
EP3765070A4 (en) SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES
MX2021010417A (es) Replicas de cafe producidas a partir de componentes individuales.
CR20210471A (es) Anticuerpos claudina 6 y usos de los mismos
WO2021040736A8 (en) Tandem cd19 car-based compositions and methods for immunotherapy
EP3886877A4 (en) METHODS FOR SIMULTANEOUS EXPANSION OF SEVERAL IMMUNE CELL TYPES, RELATED COMPOSITIONS AND USES SAME IN CANCER IMMUNOTHERAPY
EP3731573A4 (en) POWER REGULATION PROCESS AND DEVICE, AND POWER REGULATION PROCESS BASED ON AN ONLINE CARRIER CURRENT
JO3770B1 (ar) جهاز لتوصيل سيور ناقلة
WO2018015810A3 (en) Multivirus-specific t cell immunotherapy
WO2019046243A3 (en) UV-INITIATED REACTIONS IN POLYMERIC MATERIALS
MX2017011753A (es) Portador de carga.
EP3734855A4 (en) METHOD AND DEVICE FOR PAIRING MULTIPLE USERS AND BASE STATION
WO2015139020A3 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers